SXTC
China SXT Pharmaceuticals, Inc. (SXTC) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Negative interest coverage and net debt above EBITDA indicate financing strain, while peers with cleaner coverage can preserve flexibility and fund growth more easily.
A 1,101-day cash conversion cycle reflects severe working-capital drag, leaving SXTC more exposed than peers to liquidity pressure if demand or collections soften.
Days sales outstanding near 465 and inventory days above 760 suggest capital is tied up far longer than peers, increasing execution risk and margin pressure.
Despite a high current ratio, the balance-sheet cushion appears less meaningful because operating cash is trapped in receivables and inventory versus more efficient peer models.
Opportunities
If working-capital efficiency improves, SXTC could release substantial cash from receivables and inventory, creating upside that peers with tighter cycles have less room to capture.
The current ratio and quick ratio are strong versus many peers, so any stabilization in collections could translate into near-term liquidity resilience and reduced refinancing pressure.
Overall Score
SXTC’s forward positioning is constrained by severe working-capital inefficiency and weak coverage metrics, while only limited liquidity-related upside offsets those peer disadvantages.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on China SXT Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
